LYN101 not checked

Shanghai TTM-Bio Technology Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“In Part A, participants will receive single dose of LYN101 administered as a subcutaneous (SC) injection. In Part B, participants will receive multiple doses of LYN101 administered as a SC injection.”In the company’s words, NCT07178327 on ClinicalTrials.gov
Tested for
Osteoporotic Fracture
Main trialPhase 1
“This is a Phase 1, two-part, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of LYN101 in healthy subjects (part A) and multiple doses in postmenopausal women with low bone mass (part B).”In the company’s words, NCT07178327 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 30 Mar 2027 Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow LYN101

Following is part of Solo: you see every change to LYN101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in